Streptococcus pyogenes or group A streptococcal infections in child: French national reference center data;Infections à Streptococcus pyogenes ou streptocoque du groupe A chez l'enfant : données du Centre national de référence (CNR)

Archives de Pediatrie

Volumn 17, Issue 2, 2010, Pages 201-208

  Bidet, P ^a,b,f   Plainvert, C ^a,c,f   Doit, C ^a,b   Mariani Kurkdjian, P ^a,b   Bonacorsi, S ^b,f   Lepoutre, A ^d   Bouvet, A ^a,c,f   Poyart, C ^a,e,f   Bingen, E ^a,b,f  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔTEL DIEU   (France)

^d INSTITUT DE VEILLE SANITAIRE   (France)

^e Institut Cochin   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; CHILD; DISEASE SURVEILLANCE; FRANCE; GROUP A STREPTOCOCCAL INFECTION; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; NONHUMAN; PRACTICE GUIDELINE; REFERENCE DATABASE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; VACCINE PRODUCTION;

ANTI-BACTERIAL AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; FASCIITIS, NECROTIZING; FRANCE; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TONSILLITIS; VIRULENCE FACTORS;

EID: 74449086137     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2009.10.005     Document Type: Article

References (67)

1. Giovannoni G. PANDAS: overview of the hypothesis. Adv Neurol 99 (2006) 159-165
2. Olivier C. Rheumatic fever-is it still a problem?. J Antimicrob Chemother 45 Suppl (2000) S13-21
3. Bisno A.L., Brito M.O., and Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 3 (2003) 191-200
4. Garnier A., Peuchmaur M., and Deschenes G. Glomérulonéphrite aiguë post-infectieuse. Nephrol Ther 20 (2008) 20
5. Cohen R., Aujard Y., Bidet P., et al. Le streptocoque du groupe A. Un pathogène majeur pour la prochaine décennie ?. Arch Pediatr 12 (2005) 1065-1067
6. Cohen R., Levy C., Ovetchkine P., et al. Evaluation of streptococcal clinical scores, rapid antigen detection tests and cultures for childhood pharyngitis. Eur J Pediatr 163 (2004) 281-282
7. Charlier-Bret N., Boucher B., Poyart C., et al. Tests de diagnostic rapide des angines à streptocoque du groupe A : étude comparative de la sensibilité et de la praticabilité de 16 dispositifs médicaux de diagnostic in vitro dans le cadre d'un contrôle du marché effectué par l'Afssaps en juillet 2002. Pathol Biol (Paris) 52 (2004) 438-443
8. Fitoussi F., Cohen R., Brami G., et al. Molecular DNA analysis for differentiation of persistence or relapse from recurrence in treatment failure of Streptococcus pyogenes pharyngitis. Eur J Clin Microbiol Infect Dis 16 (1997) 233-237
9. Ovetchkine P., Levy C., de la Rocque F., et al. Variables influencing bacteriological outcome in patients with streptococcal tonsillopharyngitis treated with penicillin V. Eur J Pediatr 161 (2002) 365-367
10. Cohen R., Levy C., Doit C., et al. Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 15 (1996) 678-682
11. Carbon C., Chatelin A., Bingen E., et al. A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci. J Antimicrob Chemother 35 (1995) 843-854
12. Aujard Y., Boucot I., Brahimi N., et al. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J 14 (1995) 295-300
13. Portier H., Bourrillon A., Lucht F., et al. Traitement des angines aiguës à streptocoque β-hémolytique du groupe A chez l'enfant par la josamycine pendant cinq jours. Arch Pediatr 8 (2001) 700-706
14. Cohen R., Reinert P., De La Rocque F., et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 21 (2002) 297-303
15. Beres S.B., Sylva G.L., Sturdevant D.E., et al. Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proc Natl Acad Sci U S A 101 (2004) 11833-11838
16. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 45 Suppl (2000) S3-12
17. Lamagni T., Efstratiou A., Vuopio-Varkila J., et al. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill 10 (2005) 9
18. Lamagni T.L., Darenberg J., Luca-Harari B., et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 46 (2008) 2359-2367
19. Musser J.M., Kapur V., Szeto J., et al. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun 63 (1995) 994-1003
20. Bouvet A. Facteurs de virulence de Streptococcus pyogenes ou streptocoque bêta-hémolytique du groupe A. Bulletin de l'Association des anciens élèves de l'Institut Pasteur 50 (2008) 5-10
21. Fraser J.D., and Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev 225 (2008) 226-243
22. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 120 (2007) 13-22
23. Sun H., Ringdahl U., Homeister J.W., et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305 (2004) 1283-1286
24. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004) 1532-1535
25. Buchanan J.T., Simpson A.J., Aziz R.K., et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 16 (2006) 396-400
26. Hidalgo-Grass C., Mishalian I., Dan-Goor M., et al. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J 25 (2006) 4628-4637
27. Tart A.H., Walker M.J., and Musser J.M. New understanding of the group A streptococcus pathogenesis cycle. Trends Microbiol 15 (2007) 318-325
28. Kotb M., Norrby-Teglund A., McGeer A., et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 8 (2002) 1398-1404
29. Maripuu L., Eriksson A., and Norgren M. Superantigen gene profile diversity among clinical group A streptococcal isolates. FEMS Immunol Med Microbiol 54 (2008) 236-244
30. McMillan D.J., Beiko R.G., Geffers R., et al. Genes for the majority of group A streptococcal virulence factors and extracellular surface proteins do not confer an increased propensity to cause invasive disease. Clin Infect Dis 43 (2006) 884-891
31. Schmitz F.J., Beyer A., Charpentier E., et al. Toxin-gene profile heterogeneity among endemic invasive European group A streptococcal isolates. J Infect Dis 188 (2003) 1578-1586
32. Johnson D.R., Stevens D.L., and Kaplan E.L. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 166 (1992) 374-382
33. Luca-Harari B., Darenberg J., Neal S., et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 47 (2009) 1155-1165
34. O'Brien K.L., Beall B., Barrett N.L., et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 35 (2002) 268-276
35. O'Loughlin R.E., Roberson A., Cieslak P.R., et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 45 (2007) 853-862
36. Tyler S.D., Johnson W.M., Huang J.C., et al. Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol 30 (1992) 3127-3131
37. Hidalgo-Grass C., Ravins M., Dan-Goor M., et al. A locus of group A streptococcus involved in invasive disease and DNA transfer. Mol Microbiol 46 (2002) 87-99
38. Bidet P., Courroux C., Salgueiro C., et al. Molecular epidemiology of the sil streptococcal invasive locus in group A streptococci causing invasive infections in French children. J Clin Microbiol 45 (2007) 2002-2004
39. Beall B., Facklam R., and Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 34 (1996) 953-958
40. Facklam R.F., Martin D.R., Lovgren M., et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin Infect Dis 34 (2002) 28-38
41. Johnson D.R., Kaplan E.L., VanGheem A., et al. Characterization of group A streptococci (Streptococcus pyogenes): correlation of M-protein and emm-gene type with T-protein agglutination pattern and serum opacity factor. J Med Microbiol 55 Pt 2 (2006) 157-164
42. Bingen E., Fitoussi F., Doit C., et al. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 44 (2000) 1453-1457
43. Franke C., Six C., Coulon L., et al. Épidémie de scarlatine et d'angine streptococcique. Hautes-Alpes et Bouches-du-Rhône, 2007. Med Mal Inf 38 Suppl (2008) S173-S174
44. Martinaud C, Doloy A, Graffin B, et al. A familial outbreak due to an emm-type 11 multiresistant strain of Streptococcus pyogenes. Clin Microbiol Infect 2009, in press.
45. Lepoutre A., Doloy A., Bidet P., et al. Infections communautaires. Infections invasives à Streptococcus pyogenes en France en 2007. Med Mal Inf 38 Suppl (2008) S114
46. Bouvet A. Dermo-hypodermites nécrosantes : données microbiologiques et pathogéniques. Med Mal Inf 30 Suppl (2000) S406-S414
47. Minodier P, Bidet P, Rallu F, Tapiero B, Bingen E, Ovetchkine P. Clinical and microbiological characteristics of group A streptococcal necrotizing fasciitis in children. Pediatr Infect Dis J 2009;28:541-3.
48. Coyle E.A., Cha R., and Rybak M.J. Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. Antimicrob Agents Chemother 47 (2003) 1752-1755
49. Stevens D.L., Gibbons A.E., Bergstrom R., et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158 (1988) 23-28
50. Zimbelman J., Palmer A., and Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 18 (1999) 1096-1100
51. Bemer-Melchior P., Juvin M.E., Tassin S., et al. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 44 (2000) 2999-3002
52. Bingen E., Bidet P., Mihaila-Amrouche L., et al. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother 48 (2004) 3559-3562
53. Clancy J., Petitpas J., Dib-Hajj F., et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol 22 (1996) 867-879
54. Seppala H., Skurnik M., Soini H., et al. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 42 (1998) 257-262
55. Sutcliffe J., Grebe T., Tait-Kamradt A., et al. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 40 (1996) 2562-2566
56. Mihaila-Amrouche L., Bouvet A., and Loubinoux J. Clonal spread of emm type 28 isolates of Streptococcus pyogenes that are multiresistant to antibiotics. J Clin Microbiol 42 (2004) 3844-3846
57. Creti R., Gherardi G., Imperi M., et al. Association of group A streptococcal emm types with virulence traits and macrolide-resistance genes is independent of the source of isolation. J Med Microbiol 54 Pt 10 (2005) 913-917
58. Reinert R.R., Lutticken R., Sutcliffe J.A., et al. Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother 48 (2004) 1369-1373
59. Tamayo J., Perez-Trallero E., Gomez-Garces J.L., et al. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother 56 (2005) 780-782
60. Guillemot D., Weber P., Bidet P., et al. Sensibilité aux macrolides et apparentés de Streptococcus pyogenes (SGA) au cours des angines aiguës en France, hiver 2005-2006. Bull Epidemiol Hebdo 33 (2007) 291-293
61. Raymond J., Schlegel L., Garnier F., et al. Molecular characterization of Streptococcus pyogenes isolates to investigate an outbreak of puerperal sepsis. Infect Control Hosp Epidemiol 26 (2005) 455-461
62. Davies H.D., McGeer A., Schwartz B., et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario group A streptococcal study group. N Engl J Med 335 (1996) 547-554
63. Robinson K.A., Rothrock G., Phan Q., et al. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis 9 (2003) 443-447
64. Severin A., Nickbarg E., Wooters J., et al. Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 189 (2007) 1514-1522
65. Hu M.C., Walls M.A., Stroop S.D., et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 70 (2002) 2171-2177
66. Kotloff K.L., Corretti M., Palmer K., et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292 (2004) 709-715
67. Olive C. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. Curr Opin Mol Ther 9 (2007) 25-34